Leap Therapeutics Inc - ESG Rating & Company Profile powered by AI
The webpage is a zero-cost E,S&G report for Leap Therapeutics Inc. Alternative companies in the rating peer group for Leap Therapeutics Inc are displayed below. This SDG score for Leap Therapeutics Inc indicates the company's reporting of the UN Sustainable Development Goals.
Leap Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.6; made up of an environmental score of 2.0, social score of 4.0 and governance score of 4.6.
3.6
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| ... | ... | ... | |
| 1546 | Valens Company Inc | 3.7 | Medium |
| 1546 | X T L Biopharmaceuticals Ltd | 3.7 | Medium |
| 1575 | Leap Therapeutics Inc | 3.6 | Medium |
| 1575 | Biogaia AB | 3.6 | Medium |
| 1575 | Healios KK | 3.6 | Medium |
| ... | ... | ... | |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Leap Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Leap Therapeutics Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Leap Therapeutics Inc report the average age of the workforce?
Sign up for free to unlockDoes Leap Therapeutics Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Leap Therapeutics Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Leap Therapeutics Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Leap Therapeutics Inc offer flexible work?
Sign up for free to unlockDoes Leap Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Leap Therapeutics Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Leap Therapeutics Inc conduct supply chain audits?
Sign up for free to unlockDoes Leap Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Leap Therapeutics Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Leap Therapeutics Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Leap Therapeutics Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Leap Therapeutics Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Leap Therapeutics Inc disclose water use targets?
Sign up for free to unlockDoes Leap Therapeutics Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Leap Therapeutics Inc have a product recall in the last two years?
Sign up for free to unlockDoes Leap Therapeutics Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Leap Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Leap Therapeutics Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Leap Therapeutics Inc disclose parental leave metrics?
Sign up for free to unlockDoes Leap Therapeutics Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Leap Therapeutics Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Leap Therapeutics Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Leap Therapeutics Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Leap Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Leap Therapeutics Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Leap Therapeutics Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Leap Therapeutics Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Leap Therapeutics Inc disclose its waste policy?
Sign up for free to unlockDoes Leap Therapeutics Inc report according to TCFD requirements?
Sign up for free to unlockDoes Leap Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Leap Therapeutics Inc disclose energy use targets?
Sign up for free to unlockDoes Leap Therapeutics Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Leap Therapeutics Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Leap Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.